---
company: Research Solutions, Inc.
ticker: RSSS
form: 8-K
filed: 2026-05-14
accession: 0001104659-26-061215
source: https://www.sec.gov/Archives/edgar/data/1386301/000110465926061215/
---

# Research Solutions (RSSS) earnings release, May 14, 2026

Research Solutions, Inc. (RSSS) · Form 8-K, Item 2.02 · Filed 2026-05-14 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1386301/000110465926061215/)

Research Solutions Reports Third Quarter Fiscal

Year 2026 Results

Reports 8.5% Increase in ARR to $22.1 Million,

Net Income of $860,000 and 14% Year-over-Year Growth in Adjusted EBITDA

HENDERSON, Nev., May 14, 2026 — Research

Solutions, Inc.

(NASDAQ: RSSS), the leading AI-powered research workflow platform, reported financial results for its fiscal third quarter ended March 31, 2026.

Fiscal Third Quarter 2026 Summary (compared to prior-year quarter)

“We introduced a pair of new AI-based products in recent months, giving Article Galaxy and Scite users the ability to search, review and acquire scientific literature within their existing

AI tools. Simplifying the process is critical in an ever-changing research environment, and these tools help us remain an integral partner with researchers. We remain focused on executing over the long term to drive value for our shareholders.” said Roy W. Olivier, President and CEO of Research Solutions. “Our third quarter results reflect the improving profitability and growth prospects of our business, even within a softer operating environment. The continued focus across our Platform business is expanding consolidated gross margin and our strategic investment in sales and marketing is helping drive upsells for existing customers and signing larger deals with new logos.”

Fiscal Third Quarter 2026 Results

Total revenue was $12.1 million, compared to $12.7 million in the year-ago quarter. Platform revenue growth was more than offset by a decline in lower margins transactions revenue.

Platform subscription revenue for the quarter was $5.2 million, a 6.69% increase from the prior-year period. The increase was primarily due to organic growth in the core B2B platform, due to a mix of new logo generation as well as upsells and cross-selling into existing customers. The quarter ended with annual recurring revenue of $22.1 million, up 8.5% year-over-year (see the Company’s definition of annual recurring revenue below).

Transaction revenue was $7.0 million, compared to $7.8 million in the third quarter of fiscal 2025. The decrease was due to lower volume from a known churned customer and a few large customers. The transaction active customer count for the quarter was 1,346, compared to 1,380 customers in the prior-year quarter (see the Company's definition of active customer accounts and transactions below).

Total gross margin improved 220 basis points from the prior-year quarter to 51.7%. The increase was primarily driven by the continued revenue mix shift to the higher-margin Platforms business.

Total operating expenses were $5.2 million, compared to $5.7 million in the third quarter of 2025. The decrease was primarily related to reduced general and administrative and stock-based compensation expenses.

Net income in the third quarter was $860,000, or $0.03 per diluted share, compared to net income of $216,000, or $0.01 per diluted share, in the prior-year quarter. Adjusted EBITDA was $1.6 million, compared to $1.4 million in the year-ago quarter (see definition and further discussion about the presentation of Adjusted

EBITDA, a non-GAAP term, below).

Conference Call

Management will host the conference call, followed by a question-and-answer period.

Date: Thursday, May 14, 2026

Time: 5:00 p.m. ET (2:00 p.m. PT)

Dial-in number: 1-203-518-9708

Conference ID: RESEARCH

The conference call will be broadcast live and available for replay until June 14, 2026 by dialing 1-412-317-6671 and using the replay ID 11160801, and via the investor relations section of the Company's website at http://researchsolutions.investorroom.com/.

Fiscal Third Quarter Financial and Operational

Summary Tables vs. Prior-Year Quarter

Active Customer Accounts, Transactions and Annual Recurring Revenue

The Company defines active customer accounts as the sum of the total quantity of customers per month for each month in the period divided by the respective number of months in the period. The quantity of customers per month is defined as customers with at least one transaction during the month.

A transaction is an order for a unit of copyrighted content fulfilled or managed in the Platform.

The Company defines annual recurring revenue (“ARR”) as the value of contracted Platform subscription recurring revenue normalized to a one-year period. For B2C ARR, this includes the annualized value of monthly subscriptions, meaning their monthly value multiplied by twelve.

Use of Non-GAAP Measure – Adjusted EBITDA

Research Solutions’ management evaluates and makes operating decisions using various financial metrics. In addition to the Company’s GAAP results, management also considers the non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP measure provides useful information about the Company’s operating results.

The tables below provide a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure. Adjusted EBITDA is defined as net income (loss), plus interest expense, other (income) expense, foreign currency transaction (gain) loss, provision for income taxes, depreciation and amortization, stock-based compensation, and other potential adjustments that may arise. Set forth below is a reconciliation of Adjusted EBITDA to net income (loss):

About Research Solutions

Research Solutions, Inc. (NASDAQ: RSSS) is a vertical SaaS and AI Company that simplifies research workflow for academic institutions, life science companies, and research organizations worldwide. As one of the only publisher-independent marketplaces for scientific, technical, and medical (STM) content, the Company uniquely... (truncated)ess to both open access and paywalled research. The platform enables organizations to discover, access, manage and analyze scientific literature more efficiently, accelerating the pace of scientific discovery. For more information and details, please visit www.researchsolutions.com

Important Cautions Regarding Forward-Looking Statements

Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates,"

"targets," "goals," "projects", "intends," "plans," "believes," "seeks,"

"estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company's most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form

10-Q, or other reports filed with the Securities and Exchange Commission. Examples of forward-looking statements in this release include statements regarding enhanced product offerings, additional customers, creating long-term value for shareholders and the Company’s prospects for growth. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company's filings with the Securities and Exchange Commission.

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited)

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Contact

Steven Hooser or John Beisler

Three Part Advisors

(214) 872-2710 shooser@threepa.com; jbeisler@threepa.com

# # #

## Financial statements

### Income Statement (Quarter Ended March 31, — Fiscal Third Quarter Financial and Operational Summary Tables vs. Prior-Year Quarter)

| | Quarter Ended March 31, – 2026 | Quarter Ended March 31, – 2025 | Quarter Ended March 31, – Change | Quarter Ended March 31, – % Change | Nine Months Ended March 31, – 2026 | Nine Months Ended March 31, – 2025 | Nine Months Ended March 31, – Change | Nine Months Ended March 31, – % Change |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue: | Platforms | 5,160,565 | 4,839,929 | 320,636 | 6.6% | 15,506,250 | 13,770,831 | 1,735,419 | 12.6% |
| Revenue: | Transactions | 6,960,996 | 7,821,434 | -860,438 | -11.0% | 20,720,147 | 22,849,233 | -2,129,086 | -9.3% |
| Revenue: | Total Revenue | 12,121,561 | 12,661,363 | -539,802 | -4.3% | 36,226,397 | 36,620,064 | -393,667 | -1.1% |
| Gross Profit: | Platforms | 4,456,896 | 4,229,623 | 227,273 | 5.4% | 13,569,545 | 11,993,516 | 1,576,029 | 13.1% |
| Gross Profit: | Transactions | 1,808,636 | 2,037,457 | -228,821 | -11.2% | 5,098,235 | 5,860,533 | -762,298 | -13.0% |
| Gross Profit: | Total Gross Profit | 6,265,532 | 6,267,080 | -1,548 | 0.0% | 18,667,780 | 17,854,049 | 813,731 | 4.6% |
| Gross profit as a % of revenue: | Platforms | 86.4% | 87.4% | -1.0% |  | 87.5% | 87.1% | 0.4% |  |
| Gross profit as a % of revenue: | Transactions | 26.0% | 26.0% | -0.1% |  | 24.6% | 25.6% | -1.0% |  |
| Gross profit as a % of revenue: | Total Gross Profit | 51.7% | 49.5% | 2.2% |  | 51.5% | 48.8% | 2.8% |  |
| Operating Expenses: | Sales and marketing | 1,508,897 | 1,607,678 | -98,781 | -6.1% | 4,824,319 | 4,141,172 | 683,147 | 16.5% |
| Operating Expenses: | Technology and product development | 1,513,074 | 1,394,936 | 118,138 | 8.5% | 4,525,646 | 4,274,543 | 251,103 | 5.9% |
| Operating Expenses: | General and administrative | 1,625,042 | 1,845,412 | -220,370 | -11.9% | 4,920,996 | 5,783,789 | -862,794 | -14.9% |
| Operating Expenses: | Depreciation and amortization | 312,402 | 312,013 | 389 | 0.1% | 944,893 | 930,341 | 14,552 | 1.6% |
| Operating Expenses: | Stock-based compensation | 248,608 | 594,639 | -346,031 | -58.2% | 674,539 | 1,546,950 | -872,411 | -56.4% |
| Operating Expenses: | Foreign currency translation loss (gain) | 12,529 | -44,519 | 57,048 | -128.1% | 31,385 | -119,205 | 150,590 | 126.3% |
| Operating Expenses: | Total Operating Expenses | 5,220,552 | 5,710,159 | -489,607 | -8.6% | 15,921,778 | 16,557,590 | -635,813 | -3.8% |
| Operating Expenses: | Income from operations | 1,044,980 | 556,921 | 488,059 | 87.6% | 2,746,002 | 1,296,459 | 1,449,544 | 111.8% |
| Other Income (Expenses): | Other expenses | -162,607 | -327,042 | 164,435 | 50.3% | -537,232 | -2,316,404 | 1,779,172 | 76.8% |
| Other Income (Expenses): | Provision for income taxes | -22,168 | -13,410 | -8,758 | -65.3% | -52,258 | -74,816 | 22,558 | 30.2% |
| Other Income (Expenses): | Total Other Expenses: | -184,775 | -340,452 | 155,677 | 45.7% | -589,490 | -2,391,220 | 1,801,730 | 75.3% |
| Other Income (Expenses): | Net income (loss) | 860,205 | 216,469 | 643,736 | 297.4% | 2,156,512 | -1,094,761 | 3,251,274 | 297.0% |
| Other Income (Expenses): | Adjusted EBITDA | 1,618,519 | 1,419,054 | 199,465 | 14.1% | 4,396,819 | 3,654,545 | 742,274 | 20.3% |

### Income Statement (Quarter Ended March 31,)

| | Quarter Ended March 31, – 2026 | Quarter Ended March 31, – 2025 | Quarter Ended March 31, – Change | Quarter Ended March 31, – % Change | Nine Months Ended March 31, – 2026 | Nine Months Ended March 31, – 2025 | Nine Months Ended March 31, – Change | Nine Months Ended March 31, – % Change |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Net Income (loss) | 860,205 | 216,469 | 643,736 | 297.4% | 2,156,512 | -1,094,761 | 3,251,274 | 297.0% |
| Add (deduct): | Other (income) expense | 162,607 | 327,042 | -164,435 | NM | 537,232 | 2,316,404 | -1,779,172 | -76.8% |
| Add (deduct): | Foreign currency translation loss (gain) | 12,529 | -44,519 | 57,048 | -128.1% | 31,385 | -119,205 | 150,590 | 126.3% |
| Add (deduct): | Provision for income taxes | 22,168 | 13,410 | 8,758 | 65.3% | 52,258 | 74,816 | -22,558 | -30.2% |
| Add (deduct): | Depreciation and amortization | 312,402 | 312,013 | 389 | 0.1% | 944,893 | 930,341 | 14,552 | 1.6% |
| Add (deduct): | Stock-based compensation | 248,608 | 594,639 | -346,031 | -58.2% | 674,539 | 1,546,950 | -872,411 | -56.4% |
| Add (deduct): | Adjusted EBITDA | 1,618,519 | 1,419,054 | 199,465 | 14.1% | 4,396,819 | 3,654,545 | 742,275 | 20.3% |

### Income Statement (Three Months Ended — (Unaudited))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 |
|---|---:|---:|---:|---:|
| Revenue: | Platforms | 5,160,565 | 4,839,929 | 15,506,250 | 13,770,831 |
| Revenue: | Transactions | 6,960,996 | 7,821,434 | 20,720,147 | 22,849,233 |
| Revenue: | Total revenue | 12,121,561 | 12,661,363 | 36,226,397 | 36,620,064 |
| Cost of revenue: | Platforms | 703,669 | 610,306 | 1,936,705 | 1,777,315 |
| Cost of revenue: | Transactions | 5,152,360 | 5,783,977 | 15,621,912 | 16,988,700 |
| Cost of revenue: | Total cost of revenue | 5,856,029 | 6,394,283 | 17,558,617 | 18,766,015 |
| Cost of revenue: | Gross profit | 6,265,532 | 6,267,080 | 18,667,780 | 17,854,049 |
| Operating expenses: | Selling, general and administrative | 4,908,149 | 5,398,145 | 14,976,885 | 15,627,248 |
| Operating expenses: | Depreciation and amortization | 312,402 | 312,013 | 944,893 | 930,341 |
| Operating expenses: | Total operating expenses | 5,220,551 | 5,710,158 | 15,921,778 | 16,557,589 |
| Operating expenses: | Income from operations | 1,044,981 | 556,922 | 2,746,002 | 1,296,460 |
| Operating expenses: | Other income | 83,919 | 78,868 | 305,897 | 496,392 |
| Operating expenses: | Accreted interest expense | -246,526 |  | -843,129 |  |
| Operating expenses: | Change in fair value of contingent earnout liability |  | -405,910 |  | -2,812,796 |
| Operating expenses: | Income (loss) before provision for income taxes | 882,374 | 229,880 | 2,208,770 | -1,019,944 |
| Operating expenses: | Provision for income taxes | -22,168 | -13,410 | -52,258 | -74,816 |
| Operating expenses: | Net income (loss) | 860,206 | 216,470 | 2,156,512 | -1,094,760 |

### Balance Sheet (Condensed Consolidated Balance Sheets (Unaudited))

| | March 31, – 2026 | June 30, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 12,050,396 | 12,227,312 |
| Current assets: | Accounts receivable, net of allowance of $94,234 and $182,324, respectively | 7,601,477 | 7,191,234 |
| Current assets: | Prepaid expenses and other current assets | 893,176 | 580,257 |
| Current assets: | Prepaid royalties | 132,426 | 925 |
| Current assets: | Total current assets | 20,677,475 | 19,999,728 |
| Non-current assets: | Property and equipment, net of accumulated depreciation of $1,003,915 and $964,883, respectively | 57,859 | 60,769 |
| Non-current assets: | Intangible assets, net of accumulated amortization of $3,648,497 and $2,736,773, respectively | 8,836,604 | 9,686,241 |
| Non-current assets: | Goodwill | 16,372,979 | 16,372,979 |
| Non-current assets: | Deposits and other assets | 998 | 957 |
| Non-current assets: | Total assets | 45,945,915 | 46,120,674 |
| Current liabilities: | Accounts payable and accrued expenses | 6,687,477 | 7,443,757 |
| Current liabilities: | Deferred revenue, current portion | 11,105,272 | 10,702,120 |
| Current liabilities: | Contingent earnout liability, current portion | 7,310,763 | 7,363,152 |
| Current liabilities: | Total current liabilities | 25,103,512 | 25,509,029 |
| Non-current liabilities: | Deferred revenue, long-term portion | 56,508 |  |
| Non-current liabilities: | Contingent earnout liability, long-term portion | 1,726,046 | 6,683,488 |
| Non-current liabilities: | Total liabilities | 26,886,066 | 32,192,517 |
| Stockholders’ equity: | Common stock; $0.001 par value; 100,000,000 shares authorized; 33,154,273 and 32,479,993 shares issued and outstanding, respectively | 33,154 | 32,480 |
| Stockholders’ equity: | Additional paid-in capital | 42,023,679 | 39,059,557 |
| Stockholders’ equity: | Accumulated deficit | -22,887,181 | -25,043,693 |
| Stockholders’ equity: | Accumulated other comprehensive loss | -109,803 | -120,187 |
| Stockholders’ equity: | Total stockholders’ equity | 19,059,849 | 13,928,157 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 45,945,915 | 46,120,674 |

### Cash Flow (Nine Months Ended — (Unaudited))

| | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 |
|---|---:|---:|
| Cash flow from operating activities: | Net income (loss) | 2,156,512 | -1,094,760 |
| Adjustment to reconcile net income (loss) to net cash provided by operating activities: | Depreciation and amortization | 944,893 | 930,341 |
| Adjustment to reconcile net income (loss) to net cash provided by operating activities: | Stock options expense | 239,818 | 146,751 |
| Adjustment to reconcile net income (loss) to net cash provided by operating activities: | Restricted common stock expense | 434,721 | 1,400,199 |
| Adjustment to reconcile net income (loss) to net cash provided by operating activities: | Accreted interest expense | 843,129 |  |
| Adjustment to reconcile net income (loss) to net cash provided by operating activities: | Adjustment to contingent earnout liability |  | 2,812,796 |
| Changes in operating assets and liabilities: | Accounts receivable | -410,243 | -754,258 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | -312,919 | 17,826 |
| Changes in operating assets and liabilities: | Prepaid royalties | -131,501 | 311,938 |
| Changes in operating assets and liabilities: | Accounts payable and accrued expenses | -724,921 | -338,502 |
| Changes in operating assets and liabilities: | Deferred revenue | 459,660 | 1,331,920 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 3,499,149 | 4,764,251 |
| Cash flow from investing activities: | Purchase of property and equipment | -28,609 | -11,571 |
| Cash flow from investing activities: | Net cash used in investing activities | -28,609 | -11,571 |
| Cash flow from financing activities: | Proceeds from the exercise of stock options | 157,500 |  |
| Cash flow from financing activities: | Common stock repurchase | -47,385 | -908,393 |
| Cash flow from financing activities: | Payment of contingent acquisition consideration - Scite and FIZ | -3,766,263 | -91,174 |
| Cash flow from financing activities: | Net cash used in financing activities | -3,656,148 | -999,567 |
| Cash flow from financing activities: | Effect of exchange rate changes | 8,692 | -1,137 |
| Cash flow from financing activities: | Net increase (decrease) in cash and cash equivalents | -176,916 | 3,751,976 |
| Cash flow from financing activities: | Cash and cash equivalents, beginning of period | 12,227,312 | 6,100,031 |
| Cash flow from financing activities: | Cash and cash equivalents, end of period | 12,050,396 | 9,852,007 |
| Supplemental disclosures of cash flow information: | Cash paid for income taxes | 52,258 | 74,816 |
| Non-cash investing and financing activities: | Contingent consideration accrual on asset acquisition | $— | 29,394 |
| Non-cash investing and financing activities: | Common stock issued for Scite earnout payment | 2,180,142 | $— |
